| Spirig HealthCare AG - Lecigon, Gel zur intestinalen Anwendung |
| 68360 | | 01 | | Lecigon | | Gel zur intestinalen Anwendung | | N04BA03 | | Levodopa, Decarboxylase Inhibitor and Comt Inhibitor | | 02.02.2022 | | |
|
| Composition |
| levodopum 20.0 mg, carbidopum monohydricum 5.0 mg corresp. carbidopum 4.6 mg, entacaponum 20.0 mg, carmellosum natricum, natrii hydroxidum, acidum hydrochloridum, aqua purificata, ad gelatum pro 1 ml corresp. natrium 1.95 - 3.24 mg. |
| Packungsbestandteile |
| Gel for intestinal application | | | | | Active Agent | Dose |
|---|
| Carbidopa Monohydrate | 5 mg correspond Carbidopa 4.6 mg | | Entacapone | 20 mg | | Levodopa | 20 mg |
| | BAG: Active Agent | Dose |
|---|
| Carbidopa Monohydrate | 235 mg | | Entacapone | 940 mg | | Levodopa | 940 mg |
| | | | Inactive agents | Dose |
|---|
| Acidum Hydrochloridum | | | Ad Gelatum | 1 ml | | Aqua Purificata | | | Carmellose Sodium | | | Sodium Hydroxide | |
| |
|
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 001 | 7 x 47 ml | 374.40 | 423.60 | B | SL | No |
|
